Furthermore, EZH2 has been linked to decreased CD58 expression in B-cell lymphoma, with high H3K27me3 levels at the CD58 promotor region, and increased CD58 expression upon EZH2 inhibition [132]. This evidence concerns the gene CD58 and B-cell non-Hodgkin lymphoma.